ISA Pharmaceuticals Co-authors Publication in Nature Reviews Cancer on Therapeutic Cancer Vaccines

04 May 2021

Oegstgeest, The Netherlands, May 04, 2021 – ISA announces publication in Nature Reviews Cancer of a review of therapeutic cancer vaccines. The paper is co-authored by ISA’s Chief Scientific Officer, Prof. Cornelis “Kees” Melief in collaboration with key opinion leaders at international institutions including the Icahn School of Medicine at Mount Sinai, New York, the Parker Institute of Cancer Immunotherapy, San Francisco, and the Leiden University Medical Center in The Netherlands. This is the link to the online article.

The Nature Reviews Cancer paper summarizes key insights gleaned from previous successful and non-successful therapeutic vaccine trials. It provides an overview

Read more »

ISA has relocated to brand new Biopartner 5 building

03 May 2021

Oegstgeest, May 3rd, 2021 – ISA is happy to announce it has moved into its new location in the Biopartner 5 building, situated in the western part of the Leiden/Oegstgeest BioScience park.

Our new address is:De Limes 72342 DH OegstgeestThe Netherlands

The novel ISA facilities constitute a doubling in size of office and lab space, compared to its former location, with possibilities to further expand. Over the past period ISA has grown substanially and will continue to do so in the coming period. This new location is perfectly suited to accommodate this growth.

The Biopartner 5 building is designed with emphasis on sustainability:

Read more »